Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, ipilimumab (IPI).
Jeffrey S. Weber
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Ragini Reiney Kudchadkar
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Geoffrey Thomas Gibney
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Bin Yu
No relevant relationships to disclose
PingYan Cheng
No relevant relationships to disclose
Alberto J Martinez
No relevant relationships to disclose
Jodi Kroeger
No relevant relationships to disclose
Donna Gallenstein
No relevant relationships to disclose
Allison Richards
No relevant relationships to disclose
Eric Welsh
No relevant relationships to disclose
Xiuhua Zhao
No relevant relationships to disclose
Xiaotao Qu
No relevant relationships to disclose
Ann Chen
No relevant relationships to disclose